KCTD6
BTB/POZ domain-containing protein KCTD6
Protein Summary
Probable substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex mediating the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes the ubiquitination of HDAC1; the function seems to depend on KCTD11:KCTD6 oligomerization. Can function as antagonist of the Hedgehog pathway by affecting the nuclear transfer of transcription factor GLI1; the function probably occurs via HDAC1 down-regulation, keeping GLI1 acetylated and inactive. Inhibits cell growth and tumorigenicity of medulloblastoma (MDB) (PubMed:21472142). Involved in regulating protein levels of ANK1 isoform Mu17 probably implicating CUL3-dependent proteasomal degradation (PubMed:22573887).
- ENST00000355076
- ENSP00000347188
- ENSG00000168301
- ENST00000404589
- ENSP00000384948
- ENST00000490264
- ENSP00000417490
- KCASH3
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
cell type or tissue | 0.72 | ||
kinase perturbation | 0.71 | ||
tissue sample | 0.68 | ||
transcription factor | 0.67 | ||
histone modification site profile | 0.65 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2.11 (req: < 5)
Gene RIFs: 3 (req: <= 3)
Antibodies: 141 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 2.11 (req: >= 5)
Gene RIFs: 3 (req: > 3)
Antibodies: 141 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0